Wuhan HUST Life Science & Technology Co., Ltd., jointly invested by Wuhan HUST High-Tech Group Ltd., Wuhan Huagong Venture Capital Co., Ltd. and Wuhan HUST Nano Medicine Co., Ltd., was established as a pharmaceutical enterprise in June 2005, specializing in manufacturing, distributing, importing and exporting active pharmaceutical ingredient, intermediate, preparation and chemical products, researching and developing chemical pharmaceutical products and support technology service.

Seated in East lake development zone, based on technology development of HUST (Huazhong University of Science & Technology), Hust-Life is devoted itself to be the top-notch pharmaceutical manufacturer with technology advantage in the filed of modified natural macromolecule pharmaceutical products. The newly-built Hust-Life API Base, with a 10000 M2 area, has a 3300 M2 chemical API workshop conforming to GMP standard, equipped with facilities for macromolecule pharmaceutical products, it has the ability of production on a large scale.

The first industrialized API item — medium Molecular Weight (MW) Hydroxyethyl Starch (HES) 200/0.5, the substance of plasma substitute which is frequently used in Europe and is the preferred remedy in curing and de ng hypovolemia and shock. It adopts advanced chemosynthesis technology which has independent intellectual property. The major technological indexes of product have attained the advanced level in China, while the quality reaches the international level.

“be professional, be the best”. It achieves the series of medium molecular weight hydroxyethyl starch and is able to support different MW HES API like Penta starch, Heta Starch and Tetra starch. It has passed GMP attestation by SFDA and will finish the registration in Russia and India this year, its products are popular welcome overseas.

With the enterprise culture “high efficiency, preciseness, conciseness & cooperation”, depending on highly professional technology & management personnel,